KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Capital Expenditures (2020 - 2025)

Aurinia Pharmaceuticals' Capital Expenditures history spans 6 years, with the latest figure at $72000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 28.57% year-over-year to $72000.0; the TTM value through Dec 2025 reached $252000.0, down 10.32%, while the annual FY2025 figure was $252000.0, 10.32% down from the prior year.
  • Capital Expenditures reached $72000.0 in Q4 2025 per AUPH's latest filing, up from $65000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.5 million in Q2 2021 to a low of -$105000.0 in Q3 2023.
  • Average Capital Expenditures over 5 years is $480450.0, with a median of $91500.0 recorded in 2024.
  • The largest YoY upside for Capital Expenditures was 353.85% in 2023 against a maximum downside of 362.5% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $930000.0 in 2021, then tumbled by 85.59% to $134000.0 in 2022, then soared by 123.13% to $299000.0 in 2023, then tumbled by 81.27% to $56000.0 in 2024, then rose by 28.57% to $72000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Capital Expenditures are $72000.0 (Q4 2025), $65000.0 (Q3 2025), and $98000.0 (Q2 2025).